Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

盈健医疗(01419)发布公告，该公司将于2026年1月5日派发截至2025年6月30日止年度末期股息每股0.03 港元。 ...

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

智通财经APP讯，盈健医疗(01419)发布公告，该公司将于2026年1月5日派发截至2025年6月30日止年度 末期股息每股0.03港元。 ...

Human Health Holdings Limited 盈健醫療集團有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號：1419) 陳健平先生，銅紫荊星章，太平紳士 （主席兼行政總裁） 彭麗嫦醫生 （首席醫務總監） 潘振邦先生 （首席營運總監） 獨立非執行董事 呂新榮博士 陳裕光先生 陳希文先生 董事名單及其角色與職能 自 2025 年 10 月 1 日起，盈健醫療集團有限公司董事會（「董事會」）成員載列如下： 執行董事 註 ： C ：有關委員會的主席 M ：有關委員會的成員 香港 董事會轄下設立3個委員會，下表提供各董事會成員在該等委員會中所擔任的職位。 | | 董事會轄下 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 陳健平先生 | | ╱ | M | M | | 彭麗嫦醫生 | | ╱ | ╱ | M | | 呂新榮博士 | | M | C | M | | 陳裕光先生 | | M | M | C | | 陳希文先生 | | C | M | M | 2025年9月25日 ...

EF001 免責聲明 EF001 其他信息 其他信息 不適用 發行人董事 執行董事陳健平先生，銅紫荊星章，太平紳士（亦為行政總裁）、彭麗嫦醫生及潘振邦先生；獨立非執行董事呂新榮 博士、陳裕光先生及陳希文先生。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 盈健醫療集團有限公司 | | 股份代號 | 01419 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止年度末期股息 | | 公告日期 | 2025年9月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年6月30日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 ...

Financial Performance - The group's revenue for the fiscal year 2025 was approximately HKD 644.4 million, an increase of about 9.1% compared to fiscal year 2024[3] - The profit attributable to the company's owners for fiscal year 2025 was approximately HKD 26.3 million, an increase of about HKD 2.1 million or approximately 8.9% from fiscal year 2024[3] - Basic earnings per share for fiscal year 2025 were approximately HKD 0.069, compared to HKD 0.064 for fiscal year 2024[5] - Gross profit for fiscal year 2025 was HKD 295.5 million, compared to HKD 269.9 million in fiscal year 2024[4] - The total comprehensive income for the year was HKD 25.2 million, compared to HKD 19.2 million in the previous year[5] - The group reported a pre-tax profit of HKD 29.9 million for fiscal year 2025, compared to HKD 26.6 million for fiscal year 2024[4] - The group reported a net profit of HKD 26.632 million, compared to HKD 24.189 million in the previous year, indicating an increase of about 10.1%[24] - Adjusted profit before tax for the group was HKD 29.942 million, up from HKD 26.564 million, marking a growth of around 9.0%[24] Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.03 for fiscal year 2025, up from HKD 0.028 in fiscal year 2024[3] - The group proposed a final dividend of HKD 0.03 per share for 2025, compared to HKD 0.028 per share in 2024, totaling HKD 11.4 million for 2025[43] Assets and Liabilities - Non-current assets increased to HKD 484,322,000 in 2025 from HKD 442,759,000 in 2024, representing a growth of 9.5%[6] - Current assets decreased to HKD 587,649,000 in 2025 from HKD 613,614,000 in 2024, a decline of 4.2%[6] - Total liabilities decreased from HKD 215,820,000 in 2024 to HKD 203,721,000 in 2025, a reduction of 5.6%[6] - Non-current liabilities increased to HKD 86,501,000 in 2025 from HKD 73,887,000 in 2024, an increase of 17.0%[7] - Total equity rose to HKD 781,749,000 in 2025 from HKD 766,666,000 in 2024, reflecting a growth of 2.0%[7] - Cash and cash equivalents decreased to HKD 439,903,000 in 2025 from HKD 489,583,000 in 2024, a decline of 10.1%[6] - The group's total liabilities amounted to HKD 290,222,000 in 2025, slightly up from HKD 289,707,000 in 2024[25] Revenue Segmentation - The external customer revenue for the general medical services segment was HKD 410.825 million, up from HKD 398.388 million, indicating a growth of about 3.6%[24] - The specialty medical services segment reported a loss of HKD 13.114 million, an improvement from a loss of HKD 39.270 million in the previous year[24] - The dental services segment generated revenue of HKD 67.757 million, compared to HKD 58.469 million, reflecting an increase of approximately 15.5%[24] - Revenue from primary healthcare services increased by approximately HKD 12.4 million or 3.1% to about HKD 410.8 million in fiscal year 2025, driven by an increase in patient visits and average spending per visit[45] - Revenue from specialist medical services rose by approximately HKD 31.9 million or 23.8% to about HKD 165.8 million in fiscal year 2025, attributed to an increase in patient visits and average spending per visit[45] - Revenue from dental services increased by approximately HKD 9.3 million or 15.9% to about HKD 67.8 million in fiscal year 2025, mainly due to increased patient visits following the acquisition of Youde Dental[45] Operational Efficiency - The group's administrative and other expenses for fiscal year 2025 were HKD 271.7 million, compared to HKD 264.0 million in fiscal year 2024[4] - The group's service costs increased by approximately HKD 28.0 million or 8.7% to about HKD 349.0 million for the fiscal year 2025, primarily due to increased payments to doctors and dentists[46] - Financing costs decreased to HKD 6.6 million in fiscal year 2025 from HKD 8.2 million in fiscal year 2024[4] - The impairment loss on trade receivables decreased to HKD 10.9 million in 2025 from HKD 11.2 million in 2024[41] Acquisitions and Market Position - The group completed the acquisition of Youde Dental in fiscal year 2025, contributing to overall revenue growth in the dental segment despite competitive pressures[59] - The acquisition of Yau Tak Dental was completed, contributing to a revenue of approximately HKD 67.8 million in FY2025, reflecting a year-on-year growth of about 15.9%[65] - The number of dental service points increased from 15 to 35, a 133% rise compared to FY2024, enhancing patient accessibility and market coverage[66] Community Engagement and Health Initiatives - The group actively participated in community health programs in collaboration with the Hong Kong government, including seasonal flu vaccination and chronic disease management initiatives[71] - The group emphasizes good corporate governance and responsible business practices, aiming to create a positive and lasting impact on the community[89] Digital Transformation and Technology Integration - In the fiscal year 2025, the group achieved significant progress in digital transformation, implementing a comprehensive clinic operation system and an all-channel sales platform to enhance customer satisfaction[70] - The group emphasizes the integration of technology into operations to enhance nursing quality and efficiency, reflecting its commitment to improving healthcare services[70] Employee and Governance - The company employed 402 full-time employees and 207 part-time employees as of June 30, 2025, compared to 388 full-time and 355 part-time employees in the previous year[107] - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions for the fiscal year 2025, except for a deviation regarding the separation of the roles of Chairman and CEO[112]

相关事件 盈健医疗(01419.HK)9月25日举行董事会会议批准年度业绩 盈健医疗(01419.HK)完成收购香港牙科诊所 经营企业75%股权 格隆汇9月15日丨盈健医疗(01419.HK)宣布，公司董事会会议将于2025年9月25日(星期四)在香港九龙九 龙湾常悦道3号企业广场2期12楼举行，藉以(其中包括)批准公司及其附属公司截至2025年6月30日止年 度业绩及其发布，以及考虑派发末期股息之建议(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Human Health Holdings Limited 盈健醫療集團有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號：1419) 董事會召開日期 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.43 條作出。 盈健醫療集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司董事會會議 將於 2025 年 9 月 25 日（星期四）在香港九龍九龍灣常悅道 3 號企業廣場 2 期 12 樓 舉行，藉以（其中包括）批准本公司及其附屬公司截至 2025 年 6 月 30 日止年度業績 及其發佈，以及考慮派發末期股息之建議（如有）。 承董事會命 盈健醫療集團有限公司 主席 陳健平 香港，2025 年 9 月 15 日 於本公告日期，董事會包括執行董事陳健平先生，銅紫荊星章，太平紳士（亦為行政總 裁）、彭麗嫦醫生及潘振邦先生；獨立非執行董事呂新榮博士、陳裕光先生及陳希文先 生。 ...